188 related articles for article (PubMed ID: 37031300)
1. Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia.
Wang X; Chen C; Vuong D; Rodriguez-Rodriguez S; Lam V; Roleder C; Wang JH; Kambhampati S; Berger A; Pennock N; Torka P; Hernandez-Ilizaliturri F; Siddiqi T; Wang L; Xia Z; Danilov AV
Leukemia; 2023 Jun; 37(6):1324-1335. PubMed ID: 37031300
[TBL] [Abstract][Full Text] [Related]
2. Neddylation inhibition upregulates PD-L1 expression and enhances the efficacy of immune checkpoint blockade in glioblastoma.
Zhou S; Zhao X; Yang Z; Yang R; Chen C; Zhao K; Wang W; Ma Y; Zhang Q; Wang X
Int J Cancer; 2019 Aug; 145(3):763-774. PubMed ID: 31044422
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells.
Best S; Lam V; Liu T; Bruss N; Kittai A; Danilova OV; Murray S; Berger A; Pennock ND; Lind EF; Danilov AV
Leukemia; 2021 Jan; 35(1):156-168. PubMed ID: 32203139
[TBL] [Abstract][Full Text] [Related]
4. The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
Foster JH; Barbieri E; Zhang L; Scorsone KA; Moreno-Smith M; Zage P; Horton TM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207315
[TBL] [Abstract][Full Text] [Related]
5. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).
Wong KM; Micel LN; Selby HM; Tan AC; Pitts TM; Bagby SM; Spreafico A; Klauck PJ; Blakemore SJ; Smith PF; McDonald A; Berger A; Tentler JJ; Eckhardt SG
Invest New Drugs; 2017 Feb; 35(1):11-25. PubMed ID: 27783255
[TBL] [Abstract][Full Text] [Related]
6. Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer.
Li L; Kang J; Zhang W; Cai L; Wang S; Liang Y; Jiang Y; Liu X; Zhang Y; Ruan H; Chen G; Wang M; Jia L
EBioMedicine; 2019 Jul; 45():81-91. PubMed ID: 31208947
[TBL] [Abstract][Full Text] [Related]
7. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
[TBL] [Abstract][Full Text] [Related]
8. Nedd8-Activating Enzyme Is a Druggable Host Dependency Factor of Human and Mouse Cytomegalovirus.
Flores-Martínez YA; Le-Trilling VTK; Trilling M
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452475
[TBL] [Abstract][Full Text] [Related]
9. Targeting protein neddylation with an NEDD8-activating enzyme inhibitor MLN4924 induced apoptosis or senescence in human lymphoma cells.
Wang Y; Luo Z; Pan Y; Wang W; Zhou X; Jeong LS; Chu Y; Liu J; Jia L
Cancer Biol Ther; 2015; 16(3):420-9. PubMed ID: 25782162
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.
Shah JJ; Jakubowiak AJ; O'Connor OA; Orlowski RZ; Harvey RD; Smith MR; Lebovic D; Diefenbach C; Kelly K; Hua Z; Berger AJ; Mulligan G; Faessel HM; Tirrell S; Dezube BJ; Lonial S
Clin Cancer Res; 2016 Jan; 22(1):34-43. PubMed ID: 26561559
[TBL] [Abstract][Full Text] [Related]
11. The NEDD8-activating enzyme inhibitor pevonedistat activates the eIF2α and mTOR pathways inducing UPR-mediated cell death in acute lymphoblastic leukemia.
Leclerc GM; Zheng S; Leclerc GJ; DeSalvo J; Swords RT; Barredo JC
Leuk Res; 2016 Nov; 50():1-10. PubMed ID: 27626202
[TBL] [Abstract][Full Text] [Related]
12. A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification.
Xu B; Deng Y; Bi R; Guo H; Shu C; Shah NK; Chang J; Liu G; Du Y; Wei W; Wang C
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1083-1093. PubMed ID: 29667067
[TBL] [Abstract][Full Text] [Related]
13. Targeting NEDD8-activating enzyme is a new approach to treat canine diffuse large B-cell lymphoma.
Assumpção ALFV; Lu Z; Marlowe KW; Shaffer KS; Pan X
Vet Comp Oncol; 2018 Dec; 16(4):606-615. PubMed ID: 30101447
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical Inhibition of Neddylation as Promising Treatments for Various Cancers.
Yin L; Xue Y; Shang Q; Zhu H; Liu M; Liu Y; Hu Q
Curr Top Med Chem; 2019; 19(12):1059-1069. PubMed ID: 30854973
[TBL] [Abstract][Full Text] [Related]
15. Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo.
Czuczman NM; Barth MJ; Gu J; Neppalli V; Mavis C; Frys SE; Hu Q; Liu S; Klener P; Vockova P; Czuczman MS; Hernandez-Ilizaliturri FJ
Blood; 2016 Mar; 127(9):1128-37. PubMed ID: 26675347
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors.
Sarantopoulos J; Shapiro GI; Cohen RB; Clark JW; Kauh JS; Weiss GJ; Cleary JM; Mahalingam D; Pickard MD; Faessel HM; Berger AJ; Burke K; Mulligan G; Dezube BJ; Harvey RD
Clin Cancer Res; 2016 Feb; 22(4):847-57. PubMed ID: 26423795
[TBL] [Abstract][Full Text] [Related]
17. Targeting Protein Neddylation for Cancer Therapy.
Zhou L; Jia L
Adv Exp Med Biol; 2020; 1217():297-315. PubMed ID: 31898235
[TBL] [Abstract][Full Text] [Related]
18. An inhibitor of apoptosis protein antagonist T-3256336 potentiates the antitumor efficacy of the Nedd8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924).
Sumi H; Inazuka M; Morimoto M; Hibino R; Hashimoto K; Ishikawa T; Kuida K; Smith PG; Yoshida S; Yabuki M
Biochem Biophys Res Commun; 2016 Nov; 480(3):380-386. PubMed ID: 27771247
[TBL] [Abstract][Full Text] [Related]
19. Overactivated neddylation pathway as a therapeutic target in lung cancer.
Li L; Wang M; Yu G; Chen P; Li H; Wei D; Zhu J; Xie L; Jia H; Shi J; Li C; Yao W; Wang Y; Gao Q; Jeong LS; Lee HW; Yu J; Hu F; Mei J; Wang P; Chu Y; Qi H; Yang M; Dong Z; Sun Y; Hoffman RM; Jia L
J Natl Cancer Inst; 2014 Jun; 106(6):dju083. PubMed ID: 24853380
[TBL] [Abstract][Full Text] [Related]
20. Neddylation: a novel modulator of the tumor microenvironment.
Zhou L; Jiang Y; Luo Q; Li L; Jia L
Mol Cancer; 2019 Apr; 18(1):77. PubMed ID: 30943988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]